SER - NYSE

Serina Therapeutics, Inc.

Serina Therapeutics, Inc.

SERยทNYSE

$5.00

+0.0000%
HealthcareBiotechnology

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$51.25M
EPS-0.6445
P/E Ratio-2.39
Earnings Date11/11/2025
Serina Therapeutics, Inc.

Serina Therapeutics, Inc. Fair Value Envelope

SER ยท NYSE

Our analysis suggests that SER has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5, this represents a potential HIDDEN relative to our calculated worth for Serina Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $5

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$14.8M
+ Cash & Equivalents$3.7M
Firm Value-$11.1M
- Debt$268.0K
Equity Value-$11.4M
/ Shares Outstanding10,250,600B
DCF Value-$1
OVERVALUED BY 122%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$8.6M
-$4.3M
-$2.1M
-$1.1M
-$535.5K
-$267.8K
-$133.9K
-$66.9K
-$33.5K
-$16.7K
Maintenance CapEx
-$2.2K
-$1.1K
-$550
-$275
-$138
-$69
-$34
-$17
-$9
-$4
Owner Earnings
-$8.6M
-$4.3M
-$2.1M
-$1.1M
-$535.7K
-$267.8K
-$133.9K
-$67.0K
-$33.5K
-$16.7K
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$7.9M
-$3.7M
-$1.7M
-$787.5K
-$364.6K
-$168.8K
-$78.1K
-$36.2K
-$16.7K
-$7.8K
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your SER research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.